SAPPHIRE: A randomized phase II study of mFOLFOX6+panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6+panitumumab in patients with colorectal cancer.

被引：5
|
作者：
Nakamura, Masato
Munemoto, Yoshinori
Takahashi, Masazumi
Kotaka, Masahito
Kuroda, Hiroaki
Kato, Takeshi
Minagawa, Noritaka
Noura, Shingo
Fukunaga, Mutsumi
Kuramochi, Hidekazu
Touyama, Tetsuo
Takahashi, Takao
Akagi, Yoshito
Satake, Hironaga
Kurosawa, Shuichi
Miura, Tomoko
Mishima, Hideyuki
Sakamoto, Junichi
Oba, Koji
Nagata, Naoki
机构：
[1] Aizawa Hosp, Matsumoto, Nagano, Japan
[2] Fukui Ken Saiseikai Hosp, Fukui, Japan
[3] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan
[4] Sano Hosp, Kobe, Hyogo, Japan
[5] Kitakyushu Gen Hosp, Kitakyushu, Fukuoka, Japan
[6] Osaka Natl Hosp, Natl Hosp Org, Osaka, Japan
[7] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan
[8] Osaka Rosai Hosp, Sakai, Osaka, Japan
[9] Hyogo Prefectural Nishinomiya Hosp, Nishinomiya, Hyogo, Japan
[10] Tokyo Womans Med Univ, Yachiyo Med Ctr, Yachiyo, Japan
[11] Nakagami Hosp, Okinawa, Japan
[12] Gifu Univ Hosp, Gifu, Japan
[13] Kurume Univ Hosp, Kurume, Fukuoka, Japan
[14] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan
[15] Takeda Pharmaceut Co Ltd, Chuo Ku, Japan
[16] Aichi Med Univ, Aichi, Japan
[17] Tokai Cent Hosp, Kakamigahara, Japan
[18] Univ Tokyo, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.729
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
729
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients with Chemotherapy-Naive Metastatic Colorectal Cancer (SAPPHIRE)
    Nagata, N.
    Mishima, H.
    Kurosawa, S.
    Oba, K.
    Sakamoto, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 80 - 80
  • [2] Safety and efficacy of mFOLFOX6+panitumumab combination therapy and 5-FU/LV + panitumumab combination therapy in patients with chemotherapy-naive metastatic colorectal cancer (SAPPHIRE)
    Nagata, N.
    Mishima, H.
    Kurosawa, S.
    Oba, K.
    Sakamoto, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 68 - 68
  • [3] SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6+panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results
    Takahashi, M.
    Munemoto, Y.
    Nakamura, M.
    Kotaka, M.
    Kuroda, H.
    Kato, T.
    Minagawa, N.
    Noura, S.
    Fukunaga, M.
    Kuramochi, H.
    Touyama, T.
    Takahashi, T.
    Akagi, Y.
    Satake, H.
    Kurosawa, S.
    Miura, T.
    Mishima, H.
    Sakamoto, J.
    Oba, K.
    Nagata, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale
    Nagata, Naoki
    Mishima, Hideyuki
    Kurosawa, Shuichi
    Oba, Koji
    Sakamoto, Junichi
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 154 - +
  • [5] Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RASWT metastatic colorectal cancer
    Modest, D. P.
    Kasper, S.
    Stintzing, S.
    Prasnikar, N.
    Mueller, L.
    Caca, K.
    Goekkurt, E.
    von Weikersthal, L. Fischer
    Kopp, H. -G.
    Trarbach, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors
    McRee, Autumn J.
    Davies, Janine M.
    Sanoff, Hanna G.
    Goldberg, Richard M.
    Bernard, Stephen
    Dees, E. Claire
    Keller, Kimberly
    Ivanova, Anastasia
    O'Neil, Bert H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 117 - 123
  • [7] A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors
    Autumn J. McRee
    Janine M. Davies
    Hanna G. Sanoff
    Richard M. Goldberg
    Stephen Bernard
    E. Claire Dees
    Kimberly Keller
    Anastasia Ivanova
    Bert H. O’Neil
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 117 - 123
  • [8] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
    Belhadef, S.
    Arab, A.
    Belmadi, M.
    Beninal, M.
    Bacha, N.
    Abdallah, R.
    Mechta, K.
    Dahmane, A.
    Mahfouf, H.
    Oukkal, M.
    Bouzid, K.
    Faraqun, S.
    Bentabak, K.
    Younes, S. Ait
    ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
  • [9] SAPPHIRE: A Randomized Phase II Study of mFOLFOX6
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 19 - 20
  • [10] TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
    Borelli, Beatrice
    Moretto, Roberto
    Lonardi, Sara
    Bonetti, Andrea
    Antoniotti, Carlotta
    Pietrantonio, Filippo
    Masi, Gianluca
    Burgio, Valentina
    Marmorino, Federica
    Salvatore, Lisa
    Rossini, Daniele
    Zaniboni, Alberto
    Zucchelli, Gemma
    Martignetti, Angelo
    Di Battista, Monica
    Pella, Nicoletta
    Passardi, Alessandro
    Boccaccino, Alessandra
    Leone, Francesco
    Colombo, Camilla
    Granetto, Cristina
    Vannini, Francesca
    Marsico, Valentina Angela
    Martinelli, Erika
    Antonuzzo, Lorenzo
    Vitello, Stefano
    Delliponti, Laura
    Boni, Luca
    Cremolini, Chiara
    Falcone, Alfredo
    ESMO OPEN, 2018, 3 (04)
12345